RT Journal Article
SR Electronic
T1 Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20168856
DO 10.1101/2020.08.06.20168856
A1 C Serre-Miranda
A1 C Nobrega
A1 S Roque
A1 J Canto-Gomes
A1 CS Silva
A1 N Vieira
A1 P Barreira-Silva
A1 P Alves-Peixoto
A1 J Cotter
A1 A Reis
A1 M Formigo
A1 H Sarmento
A1 O Pires
A1 A Carvalho
A1 DY Petrovykh
A1 L Diéguez
A1 JC Sousa
A1 N Sousa
A1 C Capela
A1 JA Palha
A1 PG Cunha
A1 M Correia-Neves
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.06.20168856.abstract
AB Commercial availability of serological tests to evaluate immunoglobulins (Ig) towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has grown exponentially since the onset of COVID-19 (Coronavirus Disease 2019) outbreak. Their thorough validation is of extreme importance before using them as epidemiological tools to infer population seroprevalence, and as complementary diagnostic tools to molecular approaches (e.g. RT-qPCR). Here we assayed commercial serological tests (semiquantitative and qualitative) from 11 suppliers in 126 samples collected from hospitalized COVID-19 patients, and from 36 healthy and HIV-infected individuals (collected at the pre-COVID-19 pandemic). Specificity was above 95% in 9 tests. Samples from COVID-19 patients were stratified by days since symptoms onset (<10, 10-15, 16-21 and >21 days). Tests sensitivity increases with time since symptoms onset, and peaks at 16-21 days for IgM and IgA (maximum: 91.2%); and from 16-21 to >21 days for IgG, depending on the test (maximum: 94.1%). Data from semiquantitative tests show that patients with severe clinical presentation have lower relative levels of IgM, IgA and IgG at <10 days since symptoms onset in comparison to patients with non-severe presentation. At >21 days since symptoms onset the relative levels of IgM and IgG (in one test) are significantly higher in patients with severe clinical presentation, suggesting a delay in the upsurge of Ig against SARS-CoV-2 in those patients.This study highlights the high specificity of most of the evaluated tests, and sensitivity heterogeneity. Considering the virus genetic evolution and population immune response to it, continuous monitoring of commercially available serological tests towards SARS-CoV-2 is necessary.Competing Interest StatementGetein kits were provided free of charge by the manufacturer. No other conflicts of interest reported.Funding StatementThis work was funded by National funds, through the Foundation for Science and Technology (FCT): projects R4COVID (596694995), UIDB/50026/2020 and UIDP/50026/2020; and by the projects NORTE-01-0145-FEDER-000013, NORTE-01-0145-FEDER-000023 and POCI-01-0145-FEDER-016428, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). CN, SR and NV are junior researchers under the scope of the FCT Transitional Rule DL57/2016. JC-G is supported by a FCT PhD grant, in the context the Doctoral Program in Aging and Chronic Diseases (PhDOC; PD/BD/137433/2018); CS is supported by a FCT PhD grant, in the context of the Doctoral Program in Applied Health Sciences (PD/BDE/142976/2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committees of both participating Hospitals (Senhora da Oliveira Hospital: 25/2020; Braga Hospital: 37/2020); the informed consent was prepared according to the Declaration of Helsinki principles, the Oviedo Convention and according to the General Data Protection Regulation: Regulation (EU) 2016/679.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article and its supplementary information file.